Tailoring Exposure for Efficacy: Next Generation PK Optimization with KinetiSol-Enabled BAE and CR Design
Many drug candidates require more than solubility enhancement to achieve optimal therapeutic performance. This presentation from Dave Miller at CRBE Summit West (2026) explores how KinetiSol™ Technology can be used to tailor pharmacokinetic (PK) profiles through advanced amorphous solid dispersion (ASD) design. Using a tetrabenazine case study, the presentation highlights how KinetiSol enabled a modified…
Read MoreFormulation Strategies for Enabling “Undevelopable” Compounds (Poster)
Many modern drug candidates fall outside traditional guidelines like Lipinski’s Rule of Five, making them difficult to formulate with conventional technologies. This poster, presented by Dave Miller at DDC (2025) and the PECK Symposium (2025), highlights how KinetiSol™ was used to formulate a poorly soluble compound with multiple developability challenges—including high dose, poor solubility, and low…
Read MoreRedefining Drug-Like Properties with KinetiSol
Christopher Lipinski’s Rule of Five (Ro5) has been used for nearly three decades to evaluate whether a compound possesses the chemical and physical properties to potentially be an orally active drug in humans. But have modern molecules and technologies rendered Lipinski’s guidelines irrelevant? The KinetiSol process accommodates high-temperature melters without issue and solvent solubility is irrelevant to…
Read More